Vicarious Surgical

Surgical Robotics · Medtech

Milestone

Vicarious Surgical board proposes dissolving and liquidating the company

The single-port surgical robot maker never found a buyer or fresh financing, leaving shareholders bracing for zero recovery.

• Vicarious Surgical's board is asking shareholders to approve a plan to dissolve the company and liquidate its assets, with a special vote set for July 21.
• Vicarious Surgical had been developing a single-port robotic system for abdominal soft-tissue surgery, aiming to compete with Intuitive's da Vinci platform.
• The board warned in its securities filing that, based on outstanding liabilities, shareholders are unlikely to receive any distribution from the wind-down.
• Vicarious reported just under $3.7 million in cash, cash equivalents and short-term investments as of March 31, saying it wasn't enough to continue as a going concern.
• The company was delisted from the NYSE earlier this year, postponed a clinical trial in 2025, and could not secure a buyer or new equity/debt financing despite months of searching.
• CFO Sarah Romano is departing Vicarious on July 22 to become CFO of rival surgical robot maker SS Innovations, starting Aug. 3.
• The proposed dissolution underscores how brutal the soft-tissue surgical robotics race has become, with Medtronic, CMR Surgical, Distalmotion and Moon Surgical all pushing new platforms against Intuitive's entrenched da Vinci franchise.